Moore et al., Brown University Women and Children Hospital, USA, reported that a new serum biochemical marker, HE4, is helpful for the early diagnosis of ovarian cancer. The combined accuracy of HE4 and CA125 is higher than that of any single marker. Related papers were published online at Gynecol Oncol on December 3, 2007.
Although CA125 can be used in patients with attachment tumors to predict whether ovarian cancer occurs, many benign gynecological lesions may also have elevated levels. To this end, researchers hope to identify new biomarkers to increase the diagnostic sensitivity and specificity of CA125.
The investigators included a total of 259 patients with aneurysm. Of the 233 patients who met the analytical criteria, 67 had aggressive ovarian epithelial cancer and 166 had benign ovarian tumors. Preoperative determination of serum CA125, soluble mesothelioma-associated peptide (SMRP), HE4, CA72-4, activin A, osteopontin, epidermal growth factor receptor (EGFR) and HER2 levels, and their final pathology The results were compared. All markers and their combinations were analyzed using a logistic regression model and sensitivity and specificity were assessed by cross-validation analysis.
The results showed that there were significant differences in the levels of markers (except HER2) between benign and ovarian cancer patients. For a single marker, HE4 is the most sensitive (72.9%) for diagnosing ovarian cancer with a specificity of 95%. For the combination of markers, the combined sensitivity of CA125 and HE4 was the highest (76.4%) and the specificity was 95%. On the basis of this, combined with other markers, the sensitivity increased extremely low. For stage I lesions, HE4 is the best single-use marker, but combined detection of CA125 or other markers does not increase its sensitivity.
Although CA125 can be used in patients with attachment tumors to predict whether ovarian cancer occurs, many benign gynecological lesions may also have elevated levels. To this end, researchers hope to identify new biomarkers to increase the diagnostic sensitivity and specificity of CA125.
The investigators included a total of 259 patients with aneurysm. Of the 233 patients who met the analytical criteria, 67 had aggressive ovarian epithelial cancer and 166 had benign ovarian tumors. Preoperative determination of serum CA125, soluble mesothelioma-associated peptide (SMRP), HE4, CA72-4, activin A, osteopontin, epidermal growth factor receptor (EGFR) and HER2 levels, and their final pathology The results were compared. All markers and their combinations were analyzed using a logistic regression model and sensitivity and specificity were assessed by cross-validation analysis.
The results showed that there were significant differences in the levels of markers (except HER2) between benign and ovarian cancer patients. For a single marker, HE4 is the most sensitive (72.9%) for diagnosing ovarian cancer with a specificity of 95%. For the combination of markers, the combined sensitivity of CA125 and HE4 was the highest (76.4%) and the specificity was 95%. On the basis of this, combined with other markers, the sensitivity increased extremely low. For stage I lesions, HE4 is the best single-use marker, but combined detection of CA125 or other markers does not increase its sensitivity.
Hydrolyzed Sponge White Powder
Sponge
Chengdu Sino Tech company , https://www.cnherbfun.cn